Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
NCT06257355

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Led by Claris Biotherapeutics, Inc. · Updated on 2026-04-07

20

Participants Needed

7

Research Sites

177 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.

CONDITIONS

Official Title

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Centrally or paracentrally located corneal scar about 2 to 5 mm in size with part of the scar within about 3.5 mm of the cornea's center
  • Corneal scar formed from a recent eye injury or infection within 7 to 30 days before screening
  • Corneal injuries include mechanical, chemical, thermal damage, bacterial keratitis, PRK, or contact lens ulcers
  • Eye shows normal healing without signs of slow recovery
  • Ability and willingness to follow all study procedures
Not Eligible

You will not qualify if you...

  • Corneal scar involving more than about 50% depth of the cornea's remaining stromal layer
  • Scar diameter larger than about 5 mm without sponsor approval
  • No part of the scar is within about 3.5 mm of the cornea's center
  • Active eye infections like bacterial, viral, fungal, or protozoal infections at screening or Day 1
  • Planned eye surgery during the treatment period
  • Any eye or systemic condition that might interfere with treatment effect or study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Loma Linda University Eye Institute

Loma Linda, California, United States, 92354

Actively Recruiting

2

Midwest Cornea Associates, LLC

Carmel, Indiana, United States, 46290

Actively Recruiting

3

Francis Price Jr, MD

Indianapolis, Indiana, United States, 46260

Actively Recruiting

4

Minnesota Eye Consultants

Minnetonka, Minnesota, United States, 55305

Actively Recruiting

5

Legacy Devers Eye Institute

Portland, Oregon, United States, 97210

Actively Recruiting

6

Stuart A. Terry, MD PA

San Antonio, Texas, United States, 78212

Actively Recruiting

7

Virginia Eye Consultants

Norfolk, Virginia, United States, 23502

Actively Recruiting

Loading map...

Research Team

C

Central Operations Representative

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here